⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13344329 | 0.68 | — | — | |
| SCHEMBL85308 | 0.68 | — | — | |
| SCHEMBL84742 | 0.68 | — | — | |
| SCHEMBL67226 | 0.67 | — | — | |
| SCHEMBL7175304 | 0.63 | — | — | |
| SCHEMBL5956216 | 0.63 | — | — | |
| SCHEMBL10214303 | 0.63 | — | — | |
| SCHEMBL12634510 | 0.63 | — | — | |
| SCHEMBL12720626 | 0.63 | — | — | |
| SCHEMBL10045219 | 0.63 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 864 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12043627-B2 | Compound and color conversion film comprising same | LG CHEM, LTD. (KR) | 2024-07-23 | — | — | US | disclosed |
| US-20240239811-A1 | 5-(5-(PIPERIDIN-4-YL)THIENO[3,2-C]PYRAZOL-2-YL]INDAZOLE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS FOR SPLICING NUCLEIC ACIDS AND FOR THE T | REMIX THERAPEUTICS INC. | 2024-07-18 | — | — | US | disclosed |
| US-20240244870-A1 | LIGHT-EMITTING DEVICE, ELECTRONIC DEVICE INCLUDING THE SAME, AND ELECTRONIC APPARATUS INCLUDING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2024-07-18 | — | — | US | disclosed |
| US-20240239836-A9 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | SAGE THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
| US-20240216378-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2024-07-04 | — | — | US | disclosed |
| US-20240208994-A1 | PLASMA KALLIKREIN INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2024-06-27 | — | — | US | disclosed |
| US-12018041-B2 | Metal tin cyclized perylene diimide derivative, method for preparing the same, and method for using the same | DALIAN UNIVERSITY OF TECHNOLOGY (CN) | 2024-06-25 | — | — | US | disclosed |
| US-20240067641-A1 | INHIBITORS OF TRIM33 AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-02-29 | — | — | US | disclosed |
| US-11912738-B2 | Neuroactive steroids and their methods of use | SAGE THERAPEUTICS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20240025874-A1 | Quinazoline Derivative Salt Crystal Form, Preparation Method and Application | Wayshire Biopharm Holding Limited (US) | 2024-01-25 | — | — | US | disclosed |
| US-7179937-B2 | Cyclopentenone derivatives for cancer therapy | DABUR RESEARCH FOUNDATION (IN) | 2007-02-20 | — | — | US | disclosed |
| US-20070032554-A1 | Treatment of stuttering and other communication disorders with norepinephrine reuptake inhibitors | ELILILLY AND COMPANY A CORPORATION | 2007-02-08 | — | — | US | disclosed |
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | JAPAN TOBACCO INC. (JP) | 2007-02-08 | — | — | US | disclosed |
| US-7173004-B2 | Macrocyclic isoquinoline peptide inhibitors of hepatitis C virus | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-06 | — | — | US | disclosed |
| US-20070027159-A1 | Therapeutic agents useful for treating pain | PURDUE PHARMA L.P. | 2007-02-01 | — | — | US | disclosed |
| US-7169925-B2 | Indole derivatives as interleukin-4 gene expression inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2007-01-30 | — | — | US | disclosed |
| US-20070015786-A1 | Treatment of hot flashes, impulse control disorders and personality change due to a general medical condition | ELI LILY AND COMPANY (US) | 2007-01-18 | — | — | US | disclosed |
| US-20070009759-A1 | Organic phosphorescent material and organic optoelectronic device | CAMBRIDGE DISPLAY TECHNOLOGY LIMITED (GB) | 2007-01-11 | — | — | US | disclosed |
| US-20060276506-A1 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION | 2006-12-07 | — | — | US | disclosed |
| US-20060178366-A1 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION | 2006-08-10 | — | — | US | disclosed |